1 |
SIGMAR1
| [2] Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases | D03742
D03742
|
Dextromethorphan
| [11] 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
2 |
IL17F
| [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Inflammatory bowel disease | D11550
D11550
|
Bimekizumab
| [3] 46 46, 97, 271 |
3 |
TPH2
| [4] Tryptophan metabolism Tryptophan metabolism, Folate biosynthesis, Metabolic pathways, Serotonergic synapse | D09973
D09973
|
Telotristat
| [1] 97 97 |
4 |
CNR1
| [4] Rap1 signaling pathway Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling | D10915
D10915
|
Cannabidiol
| [20] 2 2, 6, 8, 13, 36, 46, 51, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271 |
5 |
CNR2
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D10915
D10915
|
Cannabidiol
| [11] 97 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271 |
6 |
ADORA1
| [7] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
7 |
ADORA1
| [7] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
8 |
ADORA2A
| [7] Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
9 |
ADORA2A
| [7] Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
10 |
CSF2RA
| [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D05066
D05066
|
Molgramostim
| [3] 97 97, 229, 299 |
11 |
ACE
| [6] Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D00251
D00251
|
Captopril
| [8] 6 6, 17, 46, 86, 96, 97, 107, 271 |
12 |
HTR3C
| [2] Serotonergic synapse Serotonergic synapse, Taste transduction | D00456
D00456
|
Ondansetron
| [3] 6 6, 97, 107 |
13 |
DHFR
| [5] One carbon pool by folate One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance | D00142
D00142
|
Methotrexate
| [38] 11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 |
14 |
DRD1
| [10] Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism | D01044
D01044
|
Flupentixol
| [1] 97 97 |
15 |
DRD2
| [8] Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D01044
D01044
|
Flupentixol
| [1] 97 97 |
16 |
AGTR1
| [16] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D08146
D08146
|
Losartan
| [17] 17 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
17 |
S1PR1
| [3] FoxO signaling pathway FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10905
D10905
|
Amiselimod
| [1] 97 97 |
18 |
S1PR1
| [3] FoxO signaling pathway FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10930
D10930
|
Etrasimod
| [3] 96 96, 97, 98 |
19 |
S1PR1
| [3] FoxO signaling pathway FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10968
D10968
|
Ozanimod
| [3] 13 13, 96, 97 |
20 |
S1PR3
| [2] Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10905
D10905
|
Amiselimod
| [1] 97 97 |
21 |
S1PR3
| [2] Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10930
D10930
|
Etrasimod
| [3] 96 96, 97, 98 |
22 |
S1PR3
| [2] Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10968
D10968
|
Ozanimod
| [3] 13 13, 96, 97 |
23 |
DHFR2
| [5] One carbon pool by folate One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance | D00142
D00142
|
Methotrexate
| [38] 11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 |
24 |
HTR3D
| [2] Serotonergic synapse Serotonergic synapse, Taste transduction | D00456
D00456
|
Ondansetron
| [3] 6 6, 97, 107 |
25 |
GABRA1
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
26 |
GABRA1
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
27 |
GABRA1
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| [3] 6 6, 46, 97 |
28 |
GABRA2
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
29 |
GABRA2
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
30 |
GABRA2
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| [3] 6 6, 46, 97 |
31 |
GABRA3
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
32 |
GABRA3
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
33 |
GABRA3
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| [3] 6 6, 46, 97 |
34 |
GABRA4
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
35 |
GABRA4
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
36 |
GABRA4
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| [3] 6 6, 46, 97 |
37 |
GABRA5
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
38 |
GABRA5
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
39 |
GABRA5
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| [3] 6 6, 46, 97 |
40 |
GABRA6
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
41 |
GABRA6
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
42 |
GABRA6
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| [3] 6 6, 46, 97 |
43 |
GABRB1
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
44 |
GABRB1
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
45 |
GABRB1
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| [3] 6 6, 46, 97 |
46 |
GABRB2
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
47 |
GABRB2
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
48 |
GABRB2
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| [3] 6 6, 46, 97 |
49 |
GABRB3
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
50 |
GABRB3
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
51 |
GABRB3
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| [3] 6 6, 46, 97 |
52 |
GABRD
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
53 |
GABRD
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
54 |
GABRD
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| [3] 6 6, 46, 97 |
55 |
GABRE
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
56 |
GABRE
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
57 |
GABRE
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| [3] 6 6, 46, 97 |
58 |
GABRG1
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
59 |
GABRG1
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
60 |
GABRG1
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| [3] 6 6, 46, 97 |
61 |
GABRG2
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
62 |
GABRG2
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
63 |
GABRG2
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| [3] 6 6, 46, 97 |
64 |
GABRG3
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
65 |
GABRG3
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
66 |
GABRG3
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| [3] 6 6, 46, 97 |
67 |
GABRP
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
68 |
GABRP
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
69 |
GABRP
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| [3] 6 6, 46, 97 |
70 |
HTR3E
| [2] Serotonergic synapse Serotonergic synapse, Taste transduction | D00456
D00456
|
Ondansetron
| [3] 6 6, 97, 107 |
71 |
GRIA1
| [14] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
72 |
GRIA2
| [15] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
73 |
GRIA3
| [13] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
74 |
GRIA4
| [10] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
75 |
GRIK1
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
76 |
GRIK2
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
77 |
GRIK3
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
78 |
GRIK4
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
79 |
GRIK5
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
80 |
GRIN1
| [18] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D03742
D03742
|
Dextromethorphan
| [11] 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
81 |
GRIN2A
| [19] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D03742
D03742
|
Dextromethorphan
| [11] 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
82 |
GRIN2B
| [19] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D03742
D03742
|
Dextromethorphan
| [11] 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
83 |
GRIN2C
| [15] Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D03742
D03742
|
Dextromethorphan
| [11] 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
84 |
GRIN2D
| [15] Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D03742
D03742
|
Dextromethorphan
| [11] 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
85 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00088
D00088
|
Hydrocortisone
| [2] 97 97, 299 |
86 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00165
D00165
|
Hydrocortisone acetate
| [1] 97 97 |
87 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00246
D00246
|
Budesonide
| [4] 97 97, 98, 228, 299 |
88 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00292
D00292
|
Dexamethasone
| [8] 97 97, 162, 222, 235, 257, 283, 296, 299 |
89 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00407
D00407
|
Methylprednisolone
| [13] 97 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 |
90 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00472
D00472
|
Prednisolone
| [11] 97 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
91 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00473
D00473
|
Prednisone
| [15] 97 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331 |
92 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00689
D00689
|
Beclomethasone dipropionate
| [2] 97 97, 98 |
93 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05000
D05000
|
Methylprednisolone hemisuccinate
| [2] 97 97, 211 |
94 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D11000
D11000
|
Vamorolone
| [2] 97 97, 113 |
95 |
GUCY2C
| [2] Purine metabolism Purine metabolism, Metabolic pathways | D09355
D09355
|
Linaclotide
| [2] 6 6, 97 |
96 |
HMGCR
| [4] Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion | D07474
D07474
|
Atorvastatin
| [19] 13 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 297, 299 |
97 |
HMGCR
| [4] Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion | D08492
D08492
|
Rosuvastatin
| [11] 6 6, 18, 46, 49, 51, 56, 79, 96, 97, 271, 299 |
98 |
HPRT1
| [4] Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | D00161
D00161
|
Mercaptopurine
| [4] 65 65, 96, 97, 164 |
99 |
HPRT1
| [4] Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | D04931
D04931
|
Mercaptopurine
| [4] 65 65, 96, 97, 164 |
100 |
HTR3A
| [2] Serotonergic synapse Serotonergic synapse, Taste transduction | D00456
D00456
|
Ondansetron
| [3] 6 6, 97, 107 |
101 |
IFNAR1
| [18] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | D04554
D04554
|
Interferon beta-1a
| [4] 13 13, 26, 96, 97 |
102 |
IFNAR2
| [17] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | D04554
D04554
|
Interferon beta-1a
| [4] 13 13, 26, 96, 97 |
103 |
IL1R1
| [13] MAPK signaling pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, Th17 cell differentiation, Inflammatory mediator regulation of TRP channels, Pathogenic Escherichia coli infection, Shigellosis, Amoebiasis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Fluid shear stress and atherosclerosis | D02934
D02934
|
Anakinra
| [18] 2 2, 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 |
104 |
IL2RA
| [11] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer | D00748
D00748
|
Aldesleukin
| [6] 2 2, 35, 49, 65, 96, 97 |
105 |
IL2RA
| [11] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer | D03058
D03058
|
Basiliximab
| [6] 2 2, 50, 66, 97, 222, 228 |
106 |
IL2RA
| [11] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer | D03639
D03639
|
Daclizumab
| [8] 13 13, 56, 60, 65, 97, 107, 283, 284 |
107 |
IL2RB
| [11] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer, Transcriptional misregulation in cancer | D00748
D00748
|
Aldesleukin
| [6] 2 2, 35, 49, 65, 96, 97 |
108 |
IL2RG
| [12] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer, Inflammatory bowel disease, Primary immunodeficiency | D00748
D00748
|
Aldesleukin
| [6] 2 2, 35, 49, 65, 96, 97 |
109 |
IL4R
| [8] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Pathways in cancer, Inflammatory bowel disease | D10354
D10354
|
Dupilumab
| [5] 51 51, 97, 98, 160, 162 |
110 |
IL12A
| [25] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis | D09214
D09214
|
Ustekinumab
| [16] 37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
111 |
IL12B
| [25] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, African trypanosomiasis, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis | D09214
D09214
|
Ustekinumab
| [16] 37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
112 |
IL13
| [8] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Fc epsilon RI signaling pathway, Pathways in cancer, Asthma, Inflammatory bowel disease | D08857
D08857
|
Anrukinzumab
| [1] 97 97 |
113 |
IL13
| [8] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Fc epsilon RI signaling pathway, Pathways in cancer, Asthma, Inflammatory bowel disease | D09979
D09979
|
Tralokinumab
| [2] 85 85, 97 |
114 |
IL17A
| [6] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis | D11550
D11550
|
Bimekizumab
| [3] 46 46, 97, 271 |
115 |
ITGA4
| [14] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D08083
D08083
|
Vedolizumab
| [3] 94 94, 96, 97 |
116 |
ITGA4
| [14] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D10540
D10540
|
Abrilumab
| [2] 96 96, 97 |
117 |
ITGB7
| [11] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Human papillomavirus infection, Transcriptional misregulation in cancer, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D08083
D08083
|
Vedolizumab
| [3] 94 94, 96, 97 |
118 |
ITGB7
| [11] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Human papillomavirus infection, Transcriptional misregulation in cancer, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D09901
D09901
|
Etrolizumab
| [2] 96 96, 97 |
119 |
ITGB7
| [11] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Human papillomavirus infection, Transcriptional misregulation in cancer, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D10540
D10540
|
Abrilumab
| [2] 96 96, 97 |
120 |
JAK1
| [27] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09970
D09970
|
Tofacitinib
| [15] 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 |
121 |
JAK1
| [27] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10871
D10871
|
Filgotinib
| [6] 46 46, 53, 96, 97, 222, 271 |
122 |
JAK1
| [27] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10944
D10944
|
Itacitinib
| [4] 46 46, 51, 97, 228 |
123 |
JAK1
| [27] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10994
D10994
|
Upadacitinib
| [8] 40 40, 41, 46, 49, 96, 97, 107, 271 |
124 |
JAK2
| [24] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Adipocytokine signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09970
D09970
|
Tofacitinib
| [15] 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 |
125 |
JAK3
| [15] Chemokine signaling pathway Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Hepatitis B, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency | D09970
D09970
|
Tofacitinib
| [15] 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 |
126 |
LTB
| [3] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis | D08866
D08866
|
Baminercept
| [4] 13 13, 46, 53, 97 |
127 |
SMAD7
| [2] TGF-beta signaling pathway TGF-beta signaling pathway, Hippo signaling pathway | D10956
D10956
|
Mongersen
| [2] 96 96, 97 |
128 |
MAOA
| [14] Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism | D05458
D05458
|
Phentermine
| [1] 97 97 |
129 |
MAOB
| [14] Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism | D05458
D05458
|
Phentermine
| [1] 97 97 |
130 |
MTNR1A
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Circadian entrainment | D08170
D08170
|
Melatonin
| [12] 6 6, 8, 13, 37, 46, 49, 72, 78, 90, 97, 145, 202 |
131 |
MTNR1B
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Circadian entrainment | D08170
D08170
|
Melatonin
| [12] 6 6, 8, 13, 37, 46, 49, 72, 78, 90, 97, 145, 202 |
132 |
SERPINC1
| [1] Complement and coagulation cascades Complement and coagulation cascades | D07510
D07510
|
Parnaparin
| [1] 97 97 |
133 |
ATP4A
| [4] Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D00455
D00455
|
Omeprazole
| [14] 6 6, 8, 21, 46, 51, 85, 96, 97, 225, 271, 282, 294, 298, 299 |
134 |
ATP4B
| [4] Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D00455
D00455
|
Omeprazole
| [14] 6 6, 8, 21, 46, 51, 85, 96, 97, 225, 271, 282, 294, 298, 299 |
135 |
OPRD1
| [3] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D05113
D05113
|
Naltrexone
| [13] 6 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 |
136 |
OPRD1
| [3] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D08144
D08144
|
Loperamide
| [2] 13 13, 97 |
137 |
OPRK1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05113
D05113
|
Naltrexone
| [2] 97 97, 226 |
138 |
OPRK1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D08144
D08144
|
Loperamide
| [1] 97 97 |
139 |
OPRM1
| [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction | D05113
D05113
|
Naltrexone
| [13] 6 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 |
140 |
OPRM1
| [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction | D08144
D08144
|
Loperamide
| [2] 13 13, 97 |
141 |
IL22
| [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Th17 cell differentiation, Inflammatory bowel disease | D11953
D11953
|
Efmarodocokin alfa
| [2] 96 96, 97 |
142 |
PDCD1
| [3] Cell adhesion molecules Cell adhesion molecules, T cell receptor signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10316
D10316
|
Nivolumab
| [12] 13 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159 |
143 |
PDE2A
| [6] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
144 |
PDE2A
| [6] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
145 |
PDE3A
| [6] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
146 |
PDE3A
| [6] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
147 |
PDE3B
| [11] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
148 |
PDE3B
| [11] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
149 |
PDE4A
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
150 |
PDE4A
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
151 |
PDE4A
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D05744
D05744
|
Roflumilast
| [4] 84 84, 97, 206, 299 |
152 |
PDE4A
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D08860
D08860
|
Apremilast
| [7] 46 46, 50, 56, 97, 107, 162, 271 |
153 |
PDE4B
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
154 |
PDE4B
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
155 |
PDE4B
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D05744
D05744
|
Roflumilast
| [4] 84 84, 97, 206, 299 |
156 |
PDE4B
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D08860
D08860
|
Apremilast
| [7] 46 46, 50, 56, 97, 107, 162, 271 |
157 |
PDE4C
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
158 |
PDE4C
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
159 |
PDE4C
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D05744
D05744
|
Roflumilast
| [4] 84 84, 97, 206, 299 |
160 |
PDE4C
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D08860
D08860
|
Apremilast
| [7] 46 46, 50, 56, 97, 107, 162, 271 |
161 |
PDE4D
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
162 |
PDE4D
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
163 |
PDE4D
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D05744
D05744
|
Roflumilast
| [4] 84 84, 97, 206, 299 |
164 |
PDE4D
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D08860
D08860
|
Apremilast
| [7] 46 46, 50, 56, 97, 107, 162, 271 |
165 |
PDE1B
| [7] Purine metabolism Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
166 |
PDE1B
| [7] Purine metabolism Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
167 |
IL23A
| [9] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | D09214
D09214
|
Ustekinumab
| [16] 37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
168 |
IL23A
| [9] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | D10438
D10438
|
Guselkumab
| [5] 37 37, 41, 51, 96, 97 |
169 |
IL23A
| [9] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | D10912
D10912
|
Brazikumab
| [2] 96 96, 97 |
170 |
IL23A
| [9] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | D11052
D11052
|
Risankizumab
| [4] 37 37, 96, 97, 271 |
171 |
IL23A
| [9] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | D11123
D11123
|
Mirikizumab
| [3] 37 37, 96, 97 |
172 |
S1PR5
| [2] Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10905
D10905
|
Amiselimod
| [1] 97 97 |
173 |
S1PR5
| [2] Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10930
D10930
|
Etrasimod
| [3] 96 96, 97, 98 |
174 |
S1PR5
| [2] Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10968
D10968
|
Ozanimod
| [3] 13 13, 96, 97 |
175 |
TLR9
| [9] Toll-like receptor signaling pathway Toll-like receptor signaling pathway, Salmonella infection, Chagas disease, African trypanosomiasis, Malaria, Tuberculosis, Measles, Herpes simplex virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer | D12275
D12275
|
Cobitolimod
| [1] 97 97 |
176 |
PPARA
| [10] PPAR signaling pathway PPAR signaling pathway, cAMP signaling pathway, Adipocytokine signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hepatitis C, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy | D00565
D00565
|
Fenofibrate
| [6] 8 8, 79, 93, 94, 97, 265 |
177 |
PPARG
| [11] PPAR signaling pathway PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis | D08491
D08491
|
Rosiglitazone
| [5] 46 46, 75, 97, 222, 265 |
178 |
PPP3CA
| [33] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
179 |
PPP3CA
| [33] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184
D00184
|
Cyclosporine
| [44] 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
180 |
PPP3CA
| [33] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
181 |
PPP3CB
| [33] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
182 |
PPP3CB
| [33] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184
D00184
|
Cyclosporine
| [44] 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
183 |
PPP3CB
| [33] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
184 |
PPP3CC
| [33] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
185 |
PPP3CC
| [33] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184
D00184
|
Cyclosporine
| [44] 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
186 |
PPP3CC
| [33] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
187 |
PPP3R1
| [32] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
188 |
PPP3R1
| [32] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184
D00184
|
Cyclosporine
| [44] 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
189 |
PPP3R1
| [32] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
190 |
PPP3R2
| [32] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
191 |
PPP3R2
| [32] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184
D00184
|
Cyclosporine
| [44] 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
192 |
PPP3R2
| [32] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
193 |
PRKAA1
| [20] FoxO signaling pathway FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis | D04966
D04966
|
Metformin
| [25] 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 |
194 |
PRKAA2
| [20] FoxO signaling pathway FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis | D04966
D04966
|
Metformin
| [25] 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 |
195 |
PRKCD
| [17] Chemokine signaling pathway Chemokine signaling pathway, Autophagy - animal, Vascular smooth muscle contraction, NOD-like receptor signaling pathway, C-type lectin receptor signaling pathway, Fc gamma R-mediated phagocytosis, Neurotrophin signaling pathway, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Estrogen signaling pathway, Type II diabetes mellitus, Insulin resistance, AGE-RAGE signaling pathway in diabetic complications, Prion disease, Shigellosis, Chemical carcinogenesis - reactive oxygen species, Diabetic cardiomyopathy | D09671
D09671
|
Sotrastaurin
| [1] 97 97 |
196 |
PRKCE
| [13] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Vascular smooth muscle contraction, Apelin signaling pathway, Tight junction, Fc gamma R-mediated phagocytosis, Inflammatory mediator regulation of TRP channels, Aldosterone synthesis and secretion, Type II diabetes mellitus, Insulin resistance, AGE-RAGE signaling pathway in diabetic complications, Shigellosis, MicroRNAs in cancer | D09671
D09671
|
Sotrastaurin
| [1] 97 97 |
197 |
PRKCH
| [2] Vascular smooth muscle contraction Vascular smooth muscle contraction, Inflammatory mediator regulation of TRP channels | D09671
D09671
|
Sotrastaurin
| [1] 97 97 |
198 |
GABRQ
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
199 |
GABRQ
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
200 |
GABRQ
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D07784
D07784
|
Delorazepam
| [3] 6 6, 46, 97 |
201 |
PRKCQ
| [11] NF-kappa B signaling pathway NF-kappa B signaling pathway, Autophagy - animal, Vascular smooth muscle contraction, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Inflammatory mediator regulation of TRP channels, Adipocytokine signaling pathway, Insulin resistance, Shigellosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09671
D09671
|
Sotrastaurin
| [1] 97 97 |
202 |
PTGS1
| [5] Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes | D00109
D00109
|
Acetylsalicylic acid
| [14] 13 13, 22, 46, 49, 51, 58, 64, 86, 97, 113, 158, 210, 231, 251 |
203 |
PTGS2
| [22] Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer | D00109
D00109
|
Acetylsalicylic acid
| [14] 13 13, 22, 46, 49, 51, 58, 64, 86, 97, 113, 158, 210, 231, 251 |
204 |
SCN1A
| [1] Dopaminergic synapse Dopaminergic synapse | D00537
D00537
|
Topiramate
| [5] 97 97, 140, 144, 156, 193 |
205 |
SCN2A
| [1] Taste transduction Taste transduction | D00537
D00537
|
Topiramate
| [5] 97 97, 140, 144, 156, 193 |
206 |
SCN3A
| [1] Taste transduction Taste transduction | D00537
D00537
|
Topiramate
| [5] 97 97, 140, 144, 156, 193 |
207 |
SCN5A
| [1] Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes | D00537
D00537
|
Topiramate
| [5] 97 97, 140, 144, 156, 193 |
208 |
SCN9A
| [1] Taste transduction Taste transduction | D00537
D00537
|
Topiramate
| [5] 97 97, 140, 144, 156, 193 |
209 |
SLC5A2
| - | D10459
D10459
|
Empagliflozin
| [2] 97 97, 257 |
210 |
SLC6A2
| [1] Synaptic vesicle cycle Synaptic vesicle cycle | D05458
D05458
|
Phentermine
| [1] 97 97 |
211 |
SLC6A2
| [1] Synaptic vesicle cycle Synaptic vesicle cycle | D07448
D07448
|
Amitriptyline
| [3] 97 97, 226, 299 |
212 |
SLC6A3
| [7] Synaptic vesicle cycle Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism | D05458
D05458
|
Phentermine
| [1] 97 97 |
213 |
SLC6A4
| [2] Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D05458
D05458
|
Phentermine
| [1] 97 97 |
214 |
SLC6A4
| [2] Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D07448
D07448
|
Amitriptyline
| [4] 78 78, 97, 226, 299 |
215 |
TNF
| [67] Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D00754
D00754
|
Thalidomide
| [20] 2 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 |
216 |
TNF
| [67] Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D02597
D02597
|
Adalimumab
| [17] 19 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 |
217 |
TNF
| [67] Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D02598
D02598
|
Infliximab
| [27] 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 |
218 |
TNF
| [67] Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D03441
D03441
|
Certolizumab pegol
| [8] 37 37, 46, 49, 96, 97, 107, 226, 271 |
219 |
TNF
| [67] Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D04358
D04358
|
Golimumab
| [8] 46 46, 56, 84, 96, 97, 107, 270, 271 |
220 |
TPH1
| [4] Tryptophan metabolism Tryptophan metabolism, Folate biosynthesis, Metabolic pathways, Serotonergic synapse | D09973
D09973
|
Telotristat
| [1] 97 97 |
221 |
TYK2
| [16] Necroptosis Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19 | D09970
D09970
|
Tofacitinib
| [15] 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 |
222 |
TYK2
| [16] Necroptosis Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19 | D11817
D11817
|
Deucravacitinib
| [3] 49 49, 96, 97 |
223 |
VDR
| [5] Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation | D00187
D00187
|
Ergocalciferol
| [6] 46 46, 49, 84, 96, 97, 299 |
224 |
VDR
| [5] Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation | D00188
D00188
|
Cholecalciferol
| [24] 6 6, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299 |
225 |
XDH
| [6] Purine metabolism Purine metabolism, Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Peroxisome | D00224
D00224
|
Allopurinol
| [7] 6 6, 46, 57, 60, 66, 96, 97 |
226 |
CA2
| [7] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways, Proximal tubule bicarbonate reclamation, Collecting duct acid secretion, Gastric acid secretion, Pancreatic secretion, Bile secretion | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
227 |
CA4
| [3] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways, Proximal tubule bicarbonate reclamation | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
228 |
CACNA1C
| [34] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
229 |
CACNA1D
| [35] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
230 |
CACNA1F
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
231 |
CACNA1S
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
232 |
IL1R2
| [7] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Amoebiasis, Human T-cell leukemia virus 1 infection, Transcriptional misregulation in cancer, Prostate cancer, Fluid shear stress and atherosclerosis | D02934
D02934
|
Anakinra
| [18] 2 2, 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 |
233 |
PDE5A
| [3] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
234 |
PDE5A
| [3] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
235 |
S1PR4
| [3] FoxO signaling pathway FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10905
D10905
|
Amiselimod
| [1] 97 97 |
236 |
S1PR4
| [3] FoxO signaling pathway FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10930
D10930
|
Etrasimod
| [3] 96 96, 97, 98 |
237 |
S1PR4
| [3] FoxO signaling pathway FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10968
D10968
|
Ozanimod
| [3] 13 13, 96, 97 |
238 |
IL1RL2
| [1] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction | D12066
D12066
|
Spesolimab
| [1] 97 97 |
239 |
CD3D
| [11] Hematopoietic cell lineage Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Chagas disease, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D06314
D06314
|
Visilizumab
| [2] 96 96, 97 |
240 |
CD3E
| [11] Hematopoietic cell lineage Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Chagas disease, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D06314
D06314
|
Visilizumab
| [2] 96 96, 97 |
241 |
HTR3B
| [2] Serotonergic synapse Serotonergic synapse, Taste transduction | D00456
D00456
|
Ondansetron
| [3] 6 6, 97, 107 |
242 |
CD3G
| [10] Hematopoietic cell lineage Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Chagas disease, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer | D06314
D06314
|
Visilizumab
| [2] 96 96, 97 |
243 |
S1PR2
| [2] Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10905
D10905
|
Amiselimod
| [1] 97 97 |
244 |
S1PR2
| [2] Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10930
D10930
|
Etrasimod
| [3] 96 96, 97, 98 |
245 |
S1PR2
| [2] Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10968
D10968
|
Ozanimod
| [3] 13 13, 96, 97 |
246 |
MS4A1
| [1] Hematopoietic cell lineage Hematopoietic cell lineage | D02994
D02994
|
Rituximab
| [14] 97 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 |
247 |
CD80
| [11] Virion - Adenovirus Virion - Adenovirus, Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis | D03203
D03203
|
Abatacept
| [26] 11 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 |
248 |
CD86
| [13] Virion - Adenovirus Virion - Adenovirus, Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Kaposi sarcoma-associated herpesvirus infection, Transcriptional misregulation in cancer, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis | D03203
D03203
|
Abatacept
| [26] 11 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 |
249 |
CD40
| [17] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Malaria, Toxoplasmosis, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Transcriptional misregulation in cancer, Asthma, Autoimmune thyroid disease, Systemic lupus erythematosus, Allograft rejection, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis | D11597
D11597
|
Ravagalimab
| [2] 53 53, 97 |
250 |
NR1H4
| [1] Bile secretion Bile secretion | D00734
D00734
|
Ursodeoxycholic acid
| [4] 97 97, 234, 296, 299 |